Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and effectiveness of biosimilar abobotulinum toxin type A for moderate to severe frown lines
IRCT20200731048257N2Phase 3Completed
- Sponsor
- Ronak Pharmaceutical
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in glabellar furrowing, sponsored by Ronak Pharmaceutical. Started Oct 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on IRCT20200731048257N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200731048257N2.